Race Oncology

Get the inside scoop on Race Oncology's journey to success in 2025!   Our latest video interview with Stockhead's Road to 2025 series is now live, featuring a recap of our key 2024 achievements and our plans for the year ahead.   Watch now to learn more about our mission to deliver cancer treatments with less cardiotoxicity and what's on the horizon for our biopharmaceutical company. https://lnkd.in/gfih8k4F   #biotech #oncology #bisantrene #cardioprotection

Race was recently featured in tim boreham’s Biocurious column in Stockhead, where he outlines the company's quest to tackle the problem of chemo-induced heart damage with #bisantrene. CEO Dr Daniel Tillett is quoted in the article saying: “As a result, the damage inflicted by cancer treatments has become increasingly important. Regulators and drug companies are zeroing in on ways to mitigate or avoid the damage.” Read more: https://lnkd.in/gY4XjS4e

Race Oncology is pleased to share the latest report from MST Access, based on our submission of the ethics and regulatory package for the Phase 1 clinical trial of RC220 bisantrene. The report also notes upcoming clinical milestones, and what investors can look out for in early 2025. You can access a full copy of the report, and ask any questions directly to our management team, on Race’s Investor Hub via this link: https://lnkd.in/gSU7cDEh

Race Oncology is pleased to welcome Dr Megan Baldwin to the company board as Independent Non-Executive Director.   Dr Baldwin is a seasoned biotech leader with more than 25 years of experience, working on therapeutic drug development programs for oncology and ophthalmic indications. She is the Founder and Chief Innovation Officer of Opthea (ASX:OPT; NASDAQ:OPT). During her 10 years serving as Opthea’s CEO and Managing Director, the company’s lead asset was advanced through preclinical studies to global Phase 3 registrational trials.   Dr Baldwin’s experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread. Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentech’s commercial division. She managed competitive intelligence activities to support Genentech’s early stage oncology programs.   Race’s Executive Chair, Dr Peter Smith commented, “We are delighted to welcome Dr Megan Baldwin to our board as an Independent Non-Executive Director. She brings to the role an exceptional depth of experience in biotechnology and therapeutic drug development. Megan’s leadership at Opthea, steering the company through its global Phase 3 trials, reflects her visionary approach to addressing critical unmet medical needs. We look forward to leveraging her expertise and insights to help drive the future success of Race.”   To read the full announcement, including a video interview with Dr Baldwin, visit Race’s Investor Hub: https://lnkd.in/g7QUYez2   #BiotechLeadership #BoardAnnnouncement #Cardioprotection

Recently, Race Oncology Executive Chair Dr Peter Smith presented at the #TwilightInvestorBriefing event in Melbourne, where he discussed the latest developments from Race, including updates on RC220 #bisantrene - a breakthrough cancer treatment that dramatically reduces cardiotoxicity. 🧬 Don’t miss this opportunity to learn about high-potential biotech investments. 📊 Watch now: https://lnkd.in/geGbiT43 #CancerInnovation #BiotechInvestment

Race Oncology is pleased to share a feature report from The Australian on the submission of the human ethics application package for bisantrene RC220 Phase 1 trial in solid tumour patients.   Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated #bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form of anthracycline commonly used in chemotherapy. The ethics submission is a milestone after a year’s preparation, with the first patient recruitment expected to take place in Q1 2025.    Read the full news article via this link: https://lnkd.in/gf4vfuXt   #cardioprotection #oncology #drugdevelopment #ethicssubmission

Important Update: Race Oncology has submitted the ethics and regulatory package for our Phase 1 clinical trial of RC220 in solid tumour patients, at the Australian lead site, Southside Cancer Care Centre, under the supervision of Principal Investigator Dr Mahood Alam. Following approval, the site will be activated for patient recruitment and institutional approval, with first patient recruitment anticipated in Q1 2025. Race Chief Medical Officer, Dr Michelle Rashford commented: “This is a critical milestone for the team; selection and evaluation of an appropriate site and the start of the ethical review for this study. Once we have the approval for the lead site, the team will focus on advancing patient recruitment as efficiently as possible to commence the assessment of the cardioprotective benefits of RC220 for patients treated with anthracyclines. I thank the clinical team and George Clinical for their efforts to date.” For further information, including a video interview with CEO Dr Daniel Tillett, visit: https://lnkd.in/gZqxnNb3

We thank all our shareholders who attended the Race Oncology 2024 AGM on Monday. 2024 has been a year of important progress for Race as we advance RC220 into the clinic. With the support of our shareholders we have made significant progress in preparation for treating the first patient in Race’s Phase 1 trial with the goal of improving both treatment outcome and quality of life of cancer patients here in Australia as well as overseas. We also explored the potential of RC220 beyond protecting the heart from the accelerated ageing caused by chemotherapy, to protecting all organs of the body. For those who were unable to attend the AGM in person, you can watch a recording of the AGM, including the official Chair’s Address, CEO Presentation and Q&As, via this link: https://lnkd.in/gvHxUr-F #biotech #oncology #bisantrene #cardioprotection #accelleratedageing

Race CEO and MD Daniel Tillett speaks with Stockhead about the discovery of 39 unique FTO-binding molecules through a drug discovery program at Monash University. Watch the full interview via the link below. #drugdevelopment

Race Oncology CEO and MD Dr Daniel Tillett speaks with Proactive’s Tylah Tully about Race’s discovery of 39 FTO-binding molecules through a drug discovery program in collaboration with Monash University.   Through the state-of-the-art fragment-screening NMR technology, Race discovered unique, patentable chemical structures that bind specifically to FTO protein. This breakthrough discovery opens the opportunity for Race to lead the way in developing FTO inhibitor drugs.    To watch the video, and interact with Race’s management team, please visit Race’s Investor Hub: https://lnkd.in/gebRB3xU #drugdevelopment #drugdiscovery